Its revenue growth comes, in part, due to the expansion of its Prodisc product line used for treating cervical and lumbar spine, according to a July 24 press release.
Here are nine highlights from Centinel Spine’s Q2 revenue report:
1. Centinel saw Prodisc total disc replacement revenue of $22.1 million, up 26% year over year.
2. Worldwide Prodisc cervical revenue reached $14.6 million, with 32% year-over-year growth.
3. Centinel saw record U.S. Prodisc cervical revenue, with 42% year-over-year growth.
4. Nearly 600 surgeons in the U.S. are now using Prodisc, representing almost 40% year-over-year growth and sequential quarterly user growth of 10%.
5. This quarter marked the eighth consecutive quarter with surgeon Prodisc user growth.
6. Nearly 7,000 procedures have been completed using Centinel’s new Prodisc C Vivo & Prodisc C SK cervical system since limited U.S. release in Q3 2022.
7. Centinel saw record Prodisc C Vivo and Prodisc C SK revenue in Q2 2024, representing nearly 67% and 100% year-over-year growth, respectively.
8. A record number of new surgeons used the Match-the-Disc Prodisc C Vivo and Prodisc C SK cervical system in Q2 2024, increasing the total number of surgeons that have utilized the new system by nearly 140% year over year.
9. Over 75% of the nearly 700 surgeons that have utilized the new system to date are repeat users.
